Alumis Quarterly Income Statement
NASDAQ: ALMSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Alumis revenue and earnings
In the quarter ended Jun 30, 2026, Alumis generated $1.7 million in revenue, down 37.7% from the same quarter a year earlier. Alumis reported a net loss of $142.2 million, compared with net income of $59.3 million a year earlier. Operating margin was -8956.4%.
Diluted earnings per share came in at -$1.11, down from $0.77.
Summary generated from market data by MetaCap's automated system. Methodology
Alumis income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.66M | 1.74M | 1.93M | 2.07M | 2.67M | 17.39M | — | — | — | — | — | — |
| Revenue growth (YoY) | -37.66% | -89.99% | — | — | — | — | — | — | — | — | — | — |
| Operating Expenses | 150.52M | 100.15M | 98.37M | 117.36M | 143.21M | 118.92M | 98.62M | 98.40M | 56.14M | 47.59M | 40.13M | 43.76M |
| Research & Development | 85.34M | 81.54M | 82.78M | 97.84M | 108.75M | 96.62M | 87.20M | 87.82M | 48.56M | 41.96M | 34.60M | 37.79M |
| Operating Income | -148.85M | -98.41M | -96.44M | -115.29M | -140.54M | -101.53M | -98.62M | -98.40M | -56.14M | -47.59M | -40.13M | -43.76M |
| Other Income (Expense) | 4.88M | 5.36M | 3.51M | 4.54M | 191.30M | 2.56M | 3.86M | 5.28M | -368.00K | -2.26M | 832.00K | 382.00K |
| Pretax Income | -143.98M | — | -92.93M | -110.75M | 50.76M | — | -94.76M | -93.12M | -56.51M | — | — | — |
| Income Tax | -1.76M | — | 0 | 0 | -8.56M | — | 0 | 0 | 0 | — | — | — |
| Net Income | -142.22M | -93.05M | -92.93M | -110.75M | 59.32M | -98.96M | -94.76M | -93.12M | -56.51M | -49.85M | -39.30M | -43.38M |
| Net Income growth (YoY) | -339.75% | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -1.11 | -0.74 | -0.76 | -1.06 | 0.78 | -1.82 | 35.48 | -1.73 | -23.10 | -21.03 | — | -19.76 |
| EPS (Diluted) | -1.11 | -0.74 | -0.75 | -1.06 | 0.77 | -1.82 | 35.48 | -1.73 | -23.10 | -21.03 | — | -19.76 |
| Shares Outstanding (Basic) | 127.69M | 125.05M | — | 104.11M | 76.48M | 54.28M | — | 53.75M | 2.45M | 2.37M | — | 2.19M |
| Shares Outstanding (Diluted) | 127.69M | 125.05M | — | 104.11M | 76.64M | 65.44M | — | 53.75M | 2.45M | 2.37M | — | 2.19M |
| EBITDA | -147.98M | -97.54M | -95.58M | -114.38M | -139.67M | -100.69M | -97.80M | -97.58M | -55.38M | -46.84M | -39.41M | -43.44M |
| Operating Margin | -8956.38% | -5652.44% | -4999.74% | -5580.45% | -5271.53% | -583.86% | — | — | — | — | — | — |
| Net Margin | -8557.22% | -5344.80% | -4817.57% | -5360.70% | 2225.09% | -569.11% | — | — | — | — | — | — |
This table shows 12 quarterly periods of Alumis's income statement, from Q2 2026 back to Q3 2023, across 15 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow ALMS's reporting calendar. What is a income statement?